2.2 Empagliflozin significantly improved glucose tolerance and insulin resistance in HFD/STZ-induced T2DM mice
After treatment with Empagliflozin, random blood glucose (P < 0.05) of mice in the Empagliflozin group was significantly lower than that of the T2DM group mice (Figure 1C) and fasting blood glucose (P < 0.05) of mice in the Empagliflozin group also significantly decreased at the end of the treatment (Figure 1D). In addition, compared with the T2DM group, Empagliflozin group significantly reduced blood glucose concentration at 0 min, 15 min, 30 min, 60 min, and 120 min, whilst the AUC of blood glucose significantly decreased both in OGTT (Figure 1 E) and IPGTT (Figure 1F) (P < 0.05), prompting that Empagliflozin could improve glucose tolerance and insulin resistance in HFD/STZ-induced T2DM mice.